B cell‐activating factors in autoimmune pulmonary alveolar proteinosis

Table 1 Demographic and clinical characteristics of the subjects

			APAP			Healthy Volunteer			Disease Control
Characteristics	N	%	Median (I.Q. range ) 　　　　　or Mean ± SD	N	%	Median (I.Q. range ) 　　　　　　　or Mean ± SD	N	%	Median (I.Q. range ) 　　　　　　　or Mean ± SD
Age – years	110		55.8 ± 13.4	34		51.4 ± 6.5	13		49.2 (29.7–55.5)
Gender
Female	33	30		21	61.8		4	30.8
Male	77	70		13	38.2		9	69.2
Onset of symptom – years	110		53.0 ± 13.3
Symptoms
Dyspnea	82	74.5
Cough	54	49.1
Sputum	39	35.5
Dust exposure
Yes	45	40.9
No	65	59.1
Smoking
Current	28	25.5		4	11.8		3	23.1
Ex	43	39		12	35.3		5	38.5
Never	39	35.5		16	47.1		2	15.4
Unknown	0	0		2	5.9		3	23.1
Pulmonary function
VC, % predicted	98		90.3 ± 22.9				13		91.3 (79.8–111.0)
FVC, % predicted	98		88.9 ± 24.0				13		91.3 (79.7–109.1)
FEV_1.0, % predicted	94		95.3 ± 25.0				13		79.0 (64.1–94.6)
DLco, % predicted	97		59.1 (45.6–75.9)				13		49.4 (37.6–80.3)
PaO₂	75		68.8 ± 15.3
Serum biomarkers
KL-6, U/L	108		3799.5 (1601.0–8787.5)				13		328.0 (237.5–917.0)
SP-D, ng/ml	106		183.9 (120.6–311.5)				12		65.5 (39.0–134.8)
SP-A, ng/ml	81		96.7 (62.5–151.4)				13		40.1 (31.3–67.5)
LDH, IU/L	108		263.5 (217.8–339.8)						185.0 (144.0–219.5)
Anti-GM-CSF autoantibody, µg/ml	110		40.5 (17.1–71.8)

APAP, autoimmune pulmonary alveolar proteinosis; IQR, interquartile range; SD, standard deviation; VC, vital capacity; FVC, forced expiratory volume; FEV1, forced expiratory volume in 1 s; DLco, diffusion capacity for carbon monoxide; PaO₂, arterial partial pressure of oxygen; KL-6, Krebs von den Lungen-6; SP-D, surfactant protein-D; SP-A, surfactant protein-A; LDH; lactate dehydrogenase; GM-CSF, granulocyte-macrophage colony-stimulating factor. Data are expressed as the median (IQR) or mean ± SD

ISSN: 1750-1172